These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

174 related items for PubMed ID: 3336237

  • 21. Neoadjuvant treatment of cancer of the bladder with M-VAC/M-VEC, and bladder-sparing policy: preliminary report of a non-randomized study.
    Galante E, Ferroni C, Bianchi S, Megale C, Molinaro S, Maymone S.
    J Exp Ther Oncol; 1996 Jul; 1(4):237-41. PubMed ID: 9414410
    [Abstract] [Full Text] [Related]

  • 22. [Systemic chemotherapy for transitional cell carcinoma of the urothelium].
    Lehmann J, Retz M, Hack M, Siemer S, Stöckle M.
    Onkologie; 2003 Oct; 26 Suppl 4():18-25. PubMed ID: 14605452
    [Abstract] [Full Text] [Related]

  • 23. Retrospective analysis of the efficacy of two cycles of M-VAC neoadjuvant chemotherapy followed by radical cystectomy for muscle-invasive bladder cancer.
    Kitagawa Y, Izumi K, Miwa S, Kadono Y, Konaka H, Mizokami A, Namiki M.
    Anticancer Res; 2013 Oct; 33(10):4497-503. PubMed ID: 24123021
    [Abstract] [Full Text] [Related]

  • 24. The effect of cystectomy, and perioperative methotrexate, vinblastine, doxorubicin and cisplatin chemotherapy on the risk and pattern of relapse in patients with muscle invasive bladder cancer.
    Ennis RD, Petrylak DP, Singh P, Bagiella E, O'Toole KM, Benson MC, Olsson CA.
    J Urol; 2000 May; 163(5):1413-8. PubMed ID: 10751847
    [Abstract] [Full Text] [Related]

  • 25. Primary methotrexate, vinblastine, doxorubicin and cisplatin chemotherapy and bladder preservation in locally invasive bladder cancer: a 5-year followup.
    Srougi M, Simon SD.
    J Urol; 1994 Mar; 151(3):593-7. PubMed ID: 8308965
    [Abstract] [Full Text] [Related]

  • 26. [Neoadjuvant chemotherapy in advanced-stage bladder carcinoma. A randomized prospective study comparing MVAC and MVEEC].
    Monica B, Larosa M, Frattini A, Macaluso G, Cocconi G, Passalacqua R, Leonardi F.
    Arch Ital Urol Androl; 1994 Dec; 66(5):235-43. PubMed ID: 7812302
    [Abstract] [Full Text] [Related]

  • 27. Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin (AMVAC) as neoadjuvant chemotherapy for patients with muscle-invasive transitional cell carcinoma of the bladder.
    Blick C, Hall P, Pwint T, Al-Terkait F, Crew J, Powles T, Macaulay V, Munro N, Douglas D, Kilbey N, Protheroe A, Chester JD.
    Cancer; 2012 Aug 15; 118(16):3920-7. PubMed ID: 22614698
    [Abstract] [Full Text] [Related]

  • 28. Toxicity and results of MVAC (methotrexate, vinblastine, adriamycin and cisplatin) chemotherapy in advanced urothelial carcinoma.
    Witjes JA, Wullink M, Oosterhof GO, de Mulder P.
    Eur Urol; 1997 Aug 15; 31(4):414-9. PubMed ID: 9187900
    [Abstract] [Full Text] [Related]

  • 29. Long-term efficacy and safety outcomes of modified (simplified) MVAC (methotrexate/vinblastine/doxorubicin/cisplatin) as frontline therapy for unresectable or metastatic urothelial cancer.
    Necchi A, Mariani L, Giannatempo P, Raggi D, Farè E, Nicolai N, Piva L, Biasoni D, Catanzaro M, Torelli T, Stagni S, Maffezzini M, Pizzocaro G, De Braud FG, Gianni AM, Salvioni R.
    Clin Genitourin Cancer; 2014 Jun 15; 12(3):203-209.e1. PubMed ID: 24394493
    [Abstract] [Full Text] [Related]

  • 30. Adjuvant methotrexate, vinblastine, adriamycin, and cisplatin chemotherapy has potential to prevent recurrence of bladder tumors after surgical removal of upper urinary tract transitional cell carcinoma.
    Soga N, Arima K, Sugimura Y.
    Int J Urol; 2008 Sep 15; 15(9):800-3. PubMed ID: 18651862
    [Abstract] [Full Text] [Related]

  • 31. Dose dense MVAC prior to radical cystectomy: a real-world experience.
    Zargar H, Shah JB, van de Putte EEF, Potvin KR, Zargar-Shoshtari K, van Rhijn BW, Daneshmand S, Holzbeierlein JM, Spiess PE, Winquist E, Horenblas S, Dinney C, Black PC, Kassouf W.
    World J Urol; 2017 Nov 15; 35(11):1729-1736. PubMed ID: 28625005
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. [18F]Fluorodeoxyglucose-positron emission tomography/computed tomography response evaluation can predict histological response at surgery after induction chemotherapy for oligometastatic bladder cancer.
    Kollberg P, Almquist H, Bläckberg M, Cwikiel M, Gudjonsson S, Lyttkens K, Patschan O, Liedberg F.
    Scand J Urol; 2017 Aug 15; 51(4):308-313. PubMed ID: 28532260
    [Abstract] [Full Text] [Related]

  • 35. [Combination chemotherapy with M-VAC protocol in metastatic urothelial cancer].
    Sella A, Flex D, Gafni D, Rabinovitz O, Sulkes A, Baniel J.
    Harefuah; 1999 Feb 15; 136(4):268-71, 340, 339. PubMed ID: 10914214
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Neoadjuvant methotrexate, vinblastine, doxorubicin and cisplatin for histologically proven lymph node positive bladder cancer.
    Nieuwenhuijzen JA, Bex A, Meinhardt W, Kerst JM, Schornagel JH, VAN Tinteren H, Horenblas S.
    J Urol; 2005 Jul 15; 174(1):80-5. PubMed ID: 15947583
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. [The effectiveness of neoadjuvant chemotherapy for invasive bladder cancer].
    Nishisaka N, Wada S, Ikemoto S, Sugimura K, Nakatani T, Horii A, Yamamoto K, Kishimoto T, Kawano M, Yasumoto R, Tsujino T.
    Nihon Hinyokika Gakkai Zasshi; 1996 Nov 15; 87(11):1250-7. PubMed ID: 8969547
    [Abstract] [Full Text] [Related]

  • 40. [The role of M-VAC polychemotherapy in the treatment of advanced urothelial carcinoma of the bladder].
    Stöckle M, Meyenburg W, Wellek S, Voges G, Gertenbach U, Thüroff JW, Huber C, Hohenfellner R.
    Ann Urol (Paris); 1993 Nov 15; 27(1):51-7. PubMed ID: 7682388
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.